ENANTA PHARMACEUTICALS INC — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2021-03-02

Reporting Person: FOLETTA MARK G (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (right to buy)	$49.92	A	7500.0	Acquired	2031-03-02	Common Stock (7500.0)	Direct

Footnotes

F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.